



## Kala Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call

April 28, 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 28, 2021-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first quarter 2021 financial results on Wednesday, May 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 2777865. To access a live webcast and subsequent archived recording of the call, please visit "Events" in the "Investors" section on the Kala website at <http://kalarx.com/>.

### **About Kala Pharmaceuticals, Inc.**

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY<sup>®</sup> mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS<sup>®</sup> (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS<sup>®</sup> (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases. For more information on Kala, please visit [www.kalarx.com](http://www.kalarx.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210428005101/en/): <https://www.businesswire.com/news/home/20210428005101/en/>

### **Investor Contact:**

Hannah Deresiewicz  
[hannah.deresiewicz@sternir.com](mailto:hannah.deresiewicz@sternir.com)  
212-362-1200

Source: Kala Pharmaceuticals, Inc.